BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Almac Discovery readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Almac Discovery's drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05765812-9091@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zedoresertib: Phase 1/2 readout est. (NCT05765812)
DESCRIPTION:Zedoresertib\, phase 1/2\, Glioblastoma.\nStudy: A Study of Zed
 oresertib (Debio 0123) in Combination With Temozolomide in Adult Participa
 nts With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 
 0123) in Combination With Temozolomide and Radiotherapy in Adult Participa
 nts With Newly Diagnosed Glioblastoma\nEstimated primary completion: Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zedoresert
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5765812
URL:https://assetmemo.bio/drug/zedoresertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
